Cargando…

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of 2017. Median age was 61 (interquartile range, 55–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sidiqi, M. Hasib, Aljama, Mohammed A., Bin Riaz, Irbaz, Dispenzieri, Angela, Muchtar, Eli, Buadi, Francis K., Warsame, Rahma, Lacy, Martha Q., Dingli, David, Leung, Nelson, Gonsalves, Wilson I., Kapoor, Prashant, Kourelis, Taxiarchis V., Hogan, William J., Rajkumar, S. Vincent, Kumar, Shaji K., Gertz, Morie A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224498/ https://www.ncbi.nlm.nih.gov/pubmed/30409963 http://dx.doi.org/10.1038/s41408-018-0147-7

Ejemplares similares

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation
por: Sidiqi, M. Hasib, et al.
Publicado: (2018)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
por: Al Saleh, Abdullah S., et al.
Publicado: (2022)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

P-207: Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis
por: Visram, Alissa, et al.
Publicado: (2021)

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
por: Abdallah, Nadine, et al.
Publicado: (2022)

Second- and third-line treatment strategies in multiple myeloma: a referral-center experience
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
por: Charalampous, Charalampos, et al.
Publicado: (2022)

The Impact of Re-induction Prior to Salvage Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2019)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023)

Colon perforation in multiple myeloma patients – A complication of high‐dose steroid treatment
por: Vaxman, Iuliana, et al.
Publicado: (2020)

Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
por: Visram, Alissa, et al.
Publicado: (2021)

Outcomes after biochemical or clinical progression in patients with multiple myeloma
por: Goldman-Mazur, Sarah, et al.
Publicado: (2022)

P885: SOLITARY PLASMACYTOMA: SINGLE INSTITUTION EXPERIENCE AND SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL OUTCOMES
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome
por: Muchtar, Eli, et al.
Publicado: (2022)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
por: Goel, Utkarsh, et al.
Publicado: (2023)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis
por: Warsame, Rahma, et al.
Publicado: (2020)

Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
por: Muchtar, Eli, et al.
Publicado: (2022)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
por: Paquin, Ashley R., et al.
Publicado: (2018)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
por: Dispenzieri, Angela, et al.
Publicado: (2020)

Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
por: Visram, Alissa, et al.
Publicado: (2020)

MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
por: Mellors, Patrick W., et al.
Publicado: (2021)

Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients
por: Mellors, Patrick W., et al.
Publicado: (2021)

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
por: Ho, Matthew, et al.
Publicado: (2022)

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Conditional survival in multiple myeloma and impact of prognostic factors over time
por: Abdallah, Nadine H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ql8a1o035m4jukgmkopmvq8tdc